France’s 5-year medical cannabis pilot ends in six weeks. The decisions made at this conference will shape the permanent framework.
Cannabis Europa Paris 2026 arrives at a pivotal moment for European medical cannabis. Held just six weeks before France’s five-year pilot program concludes on March 31, 2026, this single-day conference brings together pharmaceutical executives, regulators, and healthcare providers to navigate the transition from experimental pilot to permanent pharmaceutical system.
Unlike Canada or Germany, France is embedding medical cannabis within its existing pharmaceutical system rather than creating separate cannabis-specific licenses. This creates unique opportunities for established pharmaceutical operators and significant barriers for cannabis-only companies seeking French market entry.
“
France’s 5-year medical cannabis pilot ends March 31, 2026 – just 6 weeks after this conference.
The pilot has demonstrated measurable success: 3,209 patients enrolled since 2021, with approximately 1,600-1,800 currently active in treatment. With 610 trained prescribers and 610 authorized pharmacies already in place, France has built the infrastructure for a permanent medical cannabis system.
Cannabis Europa Paris 2026 at a Glance 🇫🇷
Date
February 19, 2026 (single-day conference)
Location
Hotel de l’Industrie, Paris, France
Expected Attendance
250+ professionals, 30+ speakers
Official Website
cannabis-europa.com
Confirmed
Last verified: December 27, 2025
Paris
48.86N 2.35E
Who Should Attend Cannabis Europa Paris 2026
Cannabis Europa Paris 2026 targets senior decision-makers navigating France’s transition from pilot to permanent medical cannabis framework:
Pharmaceutical executives seeking domestic production partnerships as France prepares to localize cultivation by 2028
Medical cannabis importers positioning for the 2026-2028 window before domestic production scales
Compliance officers requiring guidance on ANSM framework navigation and EU notification requirements
Healthcare providers exploring prescriber training pathways, joining the 610 physicians already authorized
Investors evaluating France’s EUR 806 million projected market potential by 2035
EU market strategists viewing France as a critical entry point (EU’s largest hemp producer at 60-78%)
Why Cannabis Europa Paris 2026 Matters NOW
What Changed Since Last Year?
France’s medical cannabis landscape transformed significantly in 2024-2025. The pilot program, originally set to conclude in 2024, received a critical extension to March 31, 2026. More importantly, France officially notified the European Union of its draft permanent regulations, signaling the government’s commitment to establishing medical cannabis as a pharmaceutical product.
What Decisions Are Attendees Making?
Conference participants are actively closing:
- Domestic production partnerships with French cultivation license applicants
- Import supply agreements covering the 2026-2028 window
- Reimbursement positioning strategies for social security coverage
- Clinical integration contracts with the 610 authorized pharmacies
3,209 patients enrolled since 2021 with 610 trained prescribers and 610 authorized pharmacies. France is not experimenting anymore – it is building permanent pharmaceutical infrastructure.
ANSM Pilot Program Data 2024Planning Your Cannabis Europa Paris Trip
Cannabis Europa Paris 2026 is a single-day conference. Plan to arrive the evening of February 18 to maximize networking opportunities at pre-event gatherings.
🏨 Accommodation
- Hotel d’Aubusson (4-star, 5-minute walk)
- Hotel Relais Saint-Germain (boutique, 7-minute walk)
- Hotel Le Six (contemporary, 10-minute walk)
- Book early – February business travel maintains steady hotel demand
✈️ Getting There
- Charles de Gaulle (CDG): 45-60 min via RER B + Metro
- Orly (ORY): 30-40 min via Orlyval + Metro
- Eurostar: Gare du Nord, 25 min by Metro to venue
- Venue: Hotel de l’Industrie, Saint-Germain-des-Pres
📆 Schedule Overview
- Single-day conference format
- 15+ panel sessions throughout the day
- 30+ expert speakers
- Conference app typically available 2-3 weeks before
🎪 If You’re Exhibiting
- Confirm booth assignment by January 15, 2026
- Prepare French-language collateral (English acceptable)
- Ensure EU-GMP documentation is current and accessible
- Schedule meetings via the official conference app
France’s Medical Cannabis Regulatory Framework
Key Regulatory Elements for Conference Attendees
- Primary Regulator: ANSM (Agence nationale de securite du medicament et des produits de sante) – 210-day authorization timeline
- Prescriber Network: 610 physicians trained and authorized, concentrated in hospital settings and specialized pain clinics
- Pharmacy Network: 610 pharmacies authorized to dispense, with geographic distribution across metropolitan France
- Import Reliance: France currently imports 100% of medical cannabis. Domestic cultivation projected to scale 2026-2028
- Reimbursement Status: Pilot products provided free; permanent framework will establish social security reimbursement rates
- Hemp Advantage: France produces 60-78% of Europe’s industrial hemp, providing agricultural infrastructure for domestic cultivation
Understanding France’s pharmaceutical-only model is essential for attendees. Unlike other European markets, France requires partnerships with registered pharmaceutical establishments – non-French companies cannot operate independently. EU-GMP compliance and GACP certification are mandatory for any cultivation or manufacturing activities.
Related: EU Medical Cannabis Compliance Requirements🏥 France’s Medical Cannabis Pilot: The March 2026 Deadline
France launched a 5-year medical cannabis pilot program (“experimentation du cannabis medical”) on March 26, 2021, with a firm end date of March 31, 2026. This conference occurs just 6 weeks before that deadline, making it the critical gathering point for stakeholders navigating France’s transition from pilot to permanent pharmaceutical framework.
Key Facts for Conference Attendees
- ✓ Patient Enrollment: 3,209 patients enrolled since launch; approximately 1,600-1,800 currently active in the program
- ✓ Clinical Results: 52% of patients reported improvement in their condition; zero cases of abuse or dependence recorded – powerful data for permanent authorization
- ✓ Prescriber Network: 610 trained physicians authorized to prescribe; only 5 indication categories covered (refractory epilepsy, chronic pain, oncology, palliative care, MS spasticity)
- ✓ Dispensing Model: Hospital-only through 610 authorized pharmacies; no community pharmacy access during pilot (may change post-2026)
- ✓ Products Available: Oil drops, dried flower capsules, and flower for vaporization; NO smoking permitted; products imported from Canada, Germany, Denmark, Australia
- ✓ What Happens After March 31, 2026: France is embedding cannabis into its pharmaceutical system – NOT creating separate cannabis licenses. Expect continuation under ANSM oversight with expanded reimbursement pathways.
💡 Did You Know?
France is the EU’s largest hemp producer, cultivating 23,000+ hectares annually (60-78% of total EU production). However, the country has ZERO domestic medical cannabis cultivation – 100% of pilot program products are imported. This creates a significant market opportunity for international suppliers during the 2026-2028 import reliance window.
💶 Market Projections for Conference Attendees
Prohibition Partners projects France’s medical cannabis market at EUR 9.6 million in 2026, growing to EUR 806 million by 2035 – contingent on reimbursement structures. With 2.3 million potential patients if first-line treatment is authorized, France represents the largest untapped medical cannabis market in Western Europe.
Note: Final regulations expected Q4 2025 after EU Commission review. This information is for educational purposes only.
What to Prepare Before Cannabis Europa Paris
Maximize your conference ROI by arriving prepared. Use this checklist to ensure you’re ready for every business meeting and networking opportunity.
Documents to Bring
- EU-GMP certifications (current and pending)
- Import license applications or approvals
- Clinical trial data for French therapeutic targets
- Company capability decks in French and English
- Business cards (150+ for single-day event)
- Meeting confirmations and contact details
Questions to Research
- What is the reimbursement timeline for permanent framework?
- Which domestic production partnerships are still available?
- What are ANSM’s updated approval pathways post-pilot?
- How will prescriber training expand under permanent system?
- What conditions qualify (pain, epilepsy, cancer, palliative)?
- What’s the EU Commission response to French draft decree?
What to Compare
- Import pricing structures and volume commitments
- Distribution partner coverage across French regions
- Prescription software integration with French pharmacies
- Quality assurance protocols aligned with ANSM requirements
- Partnership models for pharmaceutical establishment access
- Safety reporting systems (6-month cycles years 1-2)
Frequently Asked Questions
Common questions from cannabis professionals planning to attend Cannabis Europa Paris 2026.
Is Cannabis Europa Paris a B2B-only event?
Yes. Approximately 95% of attendees represent medical cannabis companies, pharmaceutical firms, healthcare institutions, and policy organizations. This is not a consumer-focused event.
Can international attendees participate?
Absolutely. Cannabis Europa events typically draw participants from 30+ countries. The Paris edition specifically attracts EU market entrants seeking French regulatory guidance.
Is simultaneous translation available?
Conference sessions are primarily in English. Check the official site closer to the event date for any French translation services that may be offered.
What networking events are included?
Registration typically includes access to reception events. VIP and premium packages may offer additional networking sessions. Confirm inclusions when purchasing tickets.
Is virtual attendance available?
Cannabis Europa has offered hybrid options at past events. Check the official event page for 2026 virtual access details and pricing.
What is the ticket pricing?
Super Early Bird pricing starts at EUR 214.39. Prices increase after early booking periods end. Check cannabis-europa.com for current availability.
Software Solutions for European Pharmaceutical Compliance
Cannabis operations seeking to enter the French market increasingly rely on seed-to-sale platforms capable of generating EU-GMP compliant documentation and managing multi-jurisdiction regulatory reporting. These systems help operators maintain audit-ready records across cultivation, processing, and distribution activities.
Attendees at Cannabis Europa Paris often evaluate technology solutions that can adapt to ANSM reporting requirements while maintaining consistent operational workflows across multiple facilities and export destinations.
Position Your Organization Before the Pilot Ends
Cannabis Europa Paris 2026 represents the final strategic window before France’s medical cannabis framework solidifies. See how GrowerIQ helps cannabis facilities manage EU-GMP documentation and ANSM regulatory reporting.
Request Demo
About GrowerIQ
GrowerIQ is a complete cannabis production management platform. Ours is the first platform to integrate your facility systems, including sensors, building controls, QMS, and ERP, into a single simplified interface.
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.